← board
AKAN
distress 8/10 · high distress / dilution risk$8.07+0%today-92% from 52w high
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
0%
Price & events
+32.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
-15.7%
1W
-50.1%
1M
-13.9%
3M
+19.4%
6M
-91.1%
1Y
-97.2%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $16.01M
- Enterprise Value
- $27.28M
- Volume
- 2.81K
- 52 Week Range
- $2.68 – $107
- Total Shares
- 1.98M
- Float Shares
- 537.66K
- Short %
- 3.38%
- % Held by Insiders
- 0.59%
- % Held by Institutions
- 1.89%
- RVOL
- 0.01x
- Beta
- 14.16
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.